相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Qian Chen et al.
NATURE NANOTECHNOLOGY (2019)
Strategies of Combination Drug Delivery for Immune Checkpoint Blockades
Huitong Ruan et al.
ADVANCED HEALTHCARE MATERIALS (2019)
Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery
Jinqiang Wang et al.
ACS NANO (2018)
In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
Chao Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
N. Adra et al.
ANNALS OF ONCOLOGY (2018)
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
Jehad Almasri et al.
SYSTEMATIC REVIEWS (2018)
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Control of muscle formation by the fusogenic micropeptide myomixer
Pengpeng Bi et al.
SCIENCE (2017)
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Hazem E. Ghoneim et al.
CELL (2017)
Stapled RGD Peptide Enables Glioma-Targeted Drug Delivery by Overcoming Multiple Barriers
Huitong Ruan et al.
ACS APPLIED MATERIALS & INTERFACES (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Preclinical studies of 5-fluoro-2 '-deoxycytidine and tetrahydrouridine in pediatric brain tumors
Marie Morfouace et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer
Krista P. Terracina et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
Qian Chen et al.
NATURE COMMUNICATIONS (2016)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
Lei Wang et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Felicetto Ferrara
HEMATOLOGICAL ONCOLOGY (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle et al.
ONCOTARGET (2013)
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity
Amir A. Toor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice
Pierre L. Triozzi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer
Mahadev Rao et al.
CANCER RESEARCH (2011)
Role of Gene Methylation in Antitumor Immune Response: Implication for Tumor Progression
Alfonso Serrano et al.
Cancers (2011)
Recognition of NY-ESO-1+tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression
Jennifer A. Wargo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice
Christine B. Yoo et al.
CANCER PREVENTION RESEARCH (2008)
Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis
M. C. Leslie et al.
GENE THERAPY (2007)
Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models
Daniel Neureiter et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2007)
Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b
S. R. James et al.
ONCOGENE (2006)
Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma
J Yu et al.
BMC CANCER (2004)
Inhibition of DNA methylation and reactivation of silenced genes by zebularine
JC Cheng et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis
J Yu et al.
BMC CANCER (2002)
Reactivating the expression of methylation silenced genes in human cancer
AR Karpf et al.
ONCOGENE (2002)
Block copolymer self-assembly into monodispersive nanoparticles with hybrid core of antisense DNA and calcium phosphate
Y Kakizawa et al.
LANGMUIR (2002)
The MAGE proteins: Emerging roles in cell cycle progression, apoptosis, and neurogenetic disease
PA Barker et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2002)
分享论文
